Behavioral Intervention for Youth to Promote Vaping Cessation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-18
SponsorMassachusetts General Hospital
About this trial
This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.
Eligibility criteria
Qualifiers
Age 14-18 inclusive
Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months
Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO <10 ppm for those with an in person baseline visit
Report willingness to try to quit or reduce vaping in the next 30 days
Disqualifiers
Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
Unwilling to provide saliva or urine samples
Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
Trial design
Treatments tested in this trial
- QuitVaping
- This is Quitting (TIQ)
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov